Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02287779 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability Study of SHP626 in Overweight and Obese Adults
A Phase 1 study of Non-alcoholic Steatohepatitis, sponsored by Mirum Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 84
- Enrollment target
- 1
- Study location
NCT02287779 is a Phase 1 study of Non-alcoholic Steatohepatitis that has completed, run by Mirum Pharmaceuticals. The registered enrollment target is 84 participants, below the 289-participant average among 12 other Non-alcoholic Steatohepatitis trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02287779, a Phase 1 study of Non-alcoholic Steatohepatitis, has completed, sponsored by Mirum Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 84 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will investigate the safety and tolerability of daily dosing regimens of SHP626 in overweight and obese adults.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG SHP626
Study Locations (1)
Tennessee
- New Orleans Center for Clinical Research - Knoxville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2015-01-19 |
| Est. Completion | 2015-06-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02287779
The ClinicalTrials.gov registry entry for NCT02287779 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 289-participant average among 12 other Non-alcoholic Steatohepatitis trials with a reported enrollment target (71% lower). The listed sponsor is Mirum Pharmaceuticals, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-alcoholic Steatohepatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02287779 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT02287779 about?
NCT02287779 is a clinical study titled "Safety and Tolerability Study of SHP626 in Overweight and Obese Adults". This study will investigate the safety and tolerability of daily dosing regimens of SHP626 in overweight and obese adults.
What is the current status of trial NCT02287779?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 84 participants. The study started on 2015-01-19. Estimated completion is 2015-06-19.
What conditions does trial NCT02287779 study?
This clinical trial studies the following conditions: Non-alcoholic Steatohepatitis.
What interventions are being tested in trial NCT02287779?
The interventions under investigation include: Placebo (DRUG), SHP626 (DRUG).
Who is sponsoring clinical trial NCT02287779?
This trial is sponsored by Mirum Pharmaceuticals, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02287779 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-alcoholic Steatohepatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Endoscopic Ultrasound Shear Wave Elastography in Patients With Non-alcoholic Fatty Liver Disease
RECRUITING
-
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
RECRUITING · Phase 2
-
The Olmsted NAFLD Epidemiology Study (TONES)
RECRUITING · NA
-
Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)
ACTIVE NOT RECRUITING · Phase 3
-
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
COMPLETED · Phase 2
-
An Evaluation of the Safety and Efficacy of Nitazoxanide on Collagen Turnover in NASH Patients With Fibrosis
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.